Cellectis (CLLS) Reports Q4 EPS of EUR0.59
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Cellectis Reports Fourth Quarter and Full Year 2015 Financial Results
March 14, 2016 5:19 PM EDT- On track with submission of UCART19 Clinical Trial Application; Application Filed with MHRA (UK)
- Encouraging data from the First-in-Human compassionate use of UCART19
- Early opt-in by Servier into UCART19; amendment with improved economics
- Successful production of UCART19 batches in GMP conditions; the first
off-the-shelf UCART product candidate
- On track with GMP UCART123 production; IND filing expected later in 2016
- FY2015 Revenues and other income of $61.4 million (56.4 million), with an adjusted net income of $10.3 million (9.5 million)
- Strong... More
